Results 261 to 270 of about 115,871 (339)

Natural Polyphenol–Metal Supramolecular Nanocomplex for Ferroptosis Activation in Chemoresistant Hepatocellular Carcinoma

open access: yesAggregate, EarlyView.
This study presents a supramolecular nanocomplex assembled from a natural polyphenol and Cu(II) that enables cascade glutathione (GSH) depletion through synthesis inhibition, redox cycling, and Michael addition. The system induces dual cytoplasmic and mitochondrial ferroptosis in cisplatin‐resistant hepatocellular carcinoma (HCC), reverses drug ...
Yan Qin   +6 more
wiley   +1 more source

Nanozymes for Non‐Neoplastic Diseases: Catalytic Therapy Redefined

open access: yesAggregate, EarlyView.
Non‐neoplastic diseases pose a significant health burden. Nanozymes, enzyme‐like nanomaterials, offer promising strategies for regulating oxidative stress and inflammation. This review explores their development, structure–function relationships, and therapeutic potential, with a focus on precision medicine through targeted delivery and multimodal ...
Ling Mei   +8 more
wiley   +1 more source

Regulatory mechanism of ferroptosis, a new mode of cell death

open access: gold, 2019
Da Liu   +5 more
openalex   +2 more sources

Identification of ferroptosis‐related genes involved in chronic obstructive pulmonary disease based on bioinformatics analysis

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The design of the entire paper. Green part represents the bioinformatics analysis approach. Yellow part represents the ideas of animal experiment. Abstract Background Chronic obstructive pulmonary disease (COPD) is a type of chronic respiratory disease.
Xuejing Luan   +5 more
wiley   +1 more source

Back Again to the Future: A New Era for Cerebroprotection

open access: yesAnnals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Home - About - Disclaimer - Privacy